RSV Vaccine Abrysvo Approved for Individuals 60 Years and Older
Abrysvo is expected to be available in the third quarter of 2023.
Allergy and Immunology Information Center
How Do Diet and Physical Activity Affect Allergies?
With allergies causing discomfort at their best and being life-threatening at their worst, prevention and mitigation is important. When looking at outside factors that may help, patients may look to diet and exercise. What are the specific ways diet and exercise play a role in the risk of allergies?
FDA Panel Votes on Intranasal Epinephrine for Treating Severe Allergic Reactions
Intranasal epinephrine was found to be well tolerated with no significant nasal pain or irritation.
RSV Vaccine: 4 Questions Answered
The world’s first RSV vaccine could be rolled out by fall 2023, in time for the typical winter surge in RSV infections.
Unusual Food Allergy in Children: Signs of Non-IgE-Mediated Reactions
Non-IgE-mediated food allergies are on the rise in children and do not always present with an immediate, anaphylaxis-type reaction
Is There an HIV Vaccine?
May 18 is HIV Vaccine Day, created to promote awareness of HIV vaccine research. What is the current state of vaccines for preventing HIV and how have recent trials gone?
RSV Vaccine Arexvy Wins FDA Approval for Older Adults
Arexvy is expected to be available for the 2023-2024 RSV season.
Is It a Penicillin Allergy or Not? An Educational Pilot Program for Health Care Providers
Unnecessary use of alternative antibiotics in patients with suspected penicillin allergy is associated with increased risk of antibiotic resistance.
Human Metapneumovirus, or HMPV, Is Filling ICUs This Spring
A pediatric infectious disease specialist explains this little-known virus.
Lying and Vaccine Disinformation Among Parents
Approximately 25% of parents lie about their child’s COVID-19 vaccine status or don’t quarantine their children, survey findings show.
M-M-R II, Varivax, ProQuad Vaccines Approved for Intramuscular Administration
M-M-R II, Varivax, and ProQuad are supplied in single-dose vials as lyophilized vaccine for SC or IM injection after reconstitution.
Penicillin Allergies Remain in Pharmacy Records Despite De-Labeling
Patients who have their penicillin allergy de-labeled continue to experience issues accessing penicillin when their records with their pharmacy are not up-to-date.
Flu Vaccine Effective for 2022/2023 Season
Vaccine effectiveness 54% against medically attended outpatient acute respiratory infection associated with influenza A in patients younger than 65 years
ACIP: 2023 Adult Immunization Schedule Updates
Several changes have been made to the adult immunization schedule 2023.
ACIP: 2023 Child and Adolescent Immunization Schedule Updates
Several changes have been made to the child and adolescent immunization schedule for 2023.
Biden’s Plan for Ending the Emergency Declaration for COVID-19 Signals A Pivotal Point in the Pandemic – 4 Questions Answered
President Joe Biden’s intention to end the national COVID-19 emergency will have long-lasting ripple effects on federal programs such as Medicare, Medicaid, and the Children’s Health Insurance Program.
Genetic, Environmental Prenatal Risk Factors Play Role in Early Atopic Dermatitis
Nonmodifiable risk factors for atopic dermatitis include gestational diabetes, maternal history of allergy, prenatal history of eczema.
A Technicality Could Keep RSV Shots From Kids in Need
The Vaccines for Children program may not cover the RSV shot for babies because it’s not technically a vaccine.
Are Boiled Peanuts the Answer to Peanut Allergy?
Researchers used sequential doses of boiled peanuts followed by roasted peanuts to desensitize children to peanut allergy.
Uptake Low for COVID-19 Vaccine Boosters in Immunocompromised Adults
Authors found low adherence to CDC recommendations for boosters, with older adults more likely to receive at least four mRNA COVID-19 vaccine doses.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Allergy and Immunology Information Center
Loading... 
Loading...